SummitTX Capital’s BridgeBio Pharma BBIO Stock Holding History

SummitTX Capital’s Portfolio BBIO Stock Details BBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-31,253	Closed	-$2.32M	–	789
2026 Q1	$2.32M	Sell	31,253 -4,532	-13%	-$328K	0.07%	282
2025 Q4	$2.74M	Sell	35,785 -1,426	-4%	-$93.6K	0.08%	256
2025 Q3	$1.93M	Buy	37,211 +5,386	+17%	+$263K	0.08%	262
2025 Q2	$1.37M	Sell	31,825 -34,508	-52%	-$1.26M	0.06%	312
2025 Q1	$2.29M	Buy	+66,333	New	+$2.24M	0.1%	225

Other funds holding BBIO

Jupiter Topco New York $245B AUM

KKRC

Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

ACM

Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

SummitTX Capital's BBIO Position: Q2 2026 in Review

SummitTX Capital sold out of BridgeBio Pharma (BBIO) in Q2 2026, closing a stake of 31,253 shares — an estimated $2.32M sold.

SummitTX Capital first reported a position in BBIO in Q1 2025 and held it in 5 quarters. The position peaked at $2.74M in Q4 2025. 474 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

SummitTX Capital reported no remaining BridgeBio Pharma position as of Q2 2026 after selling out during the quarter.
SummitTX Capital sold 31,253 BridgeBio Pharma shares in Q2 2026, an estimated $2.32M.
SummitTX Capital first reported a position in BridgeBio Pharma in Q1 2025 and held it in 5 quarters.
SummitTX Capital's BridgeBio Pharma position peaked at $2.74M in Q4 2025.
474 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on SummitTX Capital's 13F filing for Q2 2026, filed 14 Aug 2026.